We are excited to have two very prominent oncologists in the personalized medicine arena join us, Dr. Mark Rubin and Dr. Anthony Letai, both pioneers of Precision, Personalized and Functional Oncology, present their latest research and innovations in the use of functional genomics in treating cancer.  

The February 9th, 2018 Cancer Think Tank will be focused on answering: What is Personalized Medicine? What is involved?  How do we as practitioners, scientists and researchers optimize our part in the practice?

Speakers and Panel Discussion|  1:00 p.m to 5:30 p.m

Reception/Networking|  5:30 p.m to 7:00 p.m


 

Speakers

Dr. Anthony Letai, Associate Professor at the Dana-Farber Cancer Institute

Dr. Anthony Letai, Associate Professor at the Dana-Farber Cancer Institute

Dr. Carla Grandori, CEO of SEngine Precision Medicine and President and Scientific Director of Cure First

Dr. Carla Grandori, CEO of SEngine Precision Medicine and President and Scientific Director of Cure First

Dr. Michael Churchill, Lead Scientist at SEngine Precision Medicine

Dr. Michael Churchill, Lead Scientist at SEngine Precision Medicine

Dr. Mark Rubin, Director of the Swiss Precision Medicine Initiative in Bern

Dr. Mark Rubin, Director of the Swiss Precision Medicine Initiative in Bern

Moderator

Dr. V.K. Gadi Associate Member of the Fred Hutchinson Cancer Research Center Clinical Research 

Dr. V.K. Gadi Associate Member of the Fred Hutchinson Cancer Research Center Clinical Research 

Goals of the Evening

•To gain an understanding of next generation precision medicine

•Provide an update on SEngine’s P.A.R.I.S. Test and benefit to patients

•Understanding the role community oncologists play in precision medicine


Sponsors